MedTrace Logo

Alternative Splicing and Leukemia Initiating Cells

NCT03156933 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-05-17

No results posted yet for this study

Summary

Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML.

AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs).

The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.

Conditions

Interventions

OTHER

Assessment of splicing variants

This is a biological study with primary samples without any intervention on patients.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Etienne PAUBELLE, MD, PhD · Service d'hématologie du Centre Hospitalier Lyon Sud

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-03-31
Completion
2018-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03156933 on ClinicalTrials.gov